

# Appendix

EFFICACY OF THE ANTI-CD22 RECOMBINANT IMMUNOTOXIN BL22  
IN CHEMOTHERAPY-RESISTANT HAIRY-CELL LEUKEMIAROBERT J. KREITMAN, M.D., WYNDHAM H. WILSON, M.D., PH.D., KAREN BERGERON, R.N., MIRANDA RAGGIO, R.N.,  
MARYALICE STETLER-STEVENSON, M.D., DAVID J. FITZGERALD, PH.D., AND IRA PASTAN, M.D.

## ABSTRACT

**Background** Hairy-cell leukemia that is resistant to treatment with purine analogues, including cladribine, has a poor prognosis. We tested the safety and efficacy of an immunotoxin directed against a surface antigen that is strongly expressed by leukemic hairy cells.

**Methods** RFB4(dsFv)-PE38 (BL22), a recombinant immunotoxin containing an anti-CD22 variable domain (Fv) fused to truncated *Pseudomonas* exotoxin, was administered in a dose-escalation trial by intravenous infusion every other day for a total of three doses.

**Results** Of 16 patients who were resistant to cladribine, 11 had a complete remission and 2 had a partial remission with BL22. The three patients who did not have a response received low doses of BL22 or had preexisting toxin-neutralizing antibodies. Of the 11 patients in complete remission, 2 had minimal residual disease in the bone marrow or blood. During a median follow-up of 16 months (range, 10 to 23), 3 of the 11 patients who had a complete response relapsed and were retreated; all of these patients had a second complete remission. In 2 of the 16 patients, a serious but completely reversible hemolytic-uremic syndrome developed during the second cycle of treatment with BL22. Common toxic effects included transient hypoalbuminemia and elevated aminotransferase levels.

**Conclusions** BL22 can induce complete remissions in patients with hairy-cell leukemia that is resistant to treatment with purine analogues. (N Engl J Med 2001; 345:241-7.)

Copyright © 2001 Massachusetts Medical Society.

**A**BOUT 2 percent of cases of leukemia are of the hairy-cell type.<sup>1,2</sup> Prominent features of the disease are splenomegaly, pancytopenia, and the presence of cells in the peripheral blood, spleen, and bone marrow with hair-like cytoplasmic projections.<sup>3,4</sup> Splenectomy is generally only palliative,<sup>5</sup> but interferon alfa produces a partial remission in 30 to 70 percent of patients and complete remission, often of short duration, in 5 to 10 percent.<sup>6-10</sup> The purine analogues pentostatin (2'-deoxycoformycin) and cladribine (2-chlorodeoxyadenosine) induce complete remissions in up to 85 percent of patients and partial responses in 5 to 25 percent. With such treatment, the rate of disease-free survival at eight years is 60 to 75 percent.<sup>10-13</sup> However, patients with cladribine-resistant disease have poor responses to other therapy. In the 20 percent of patients with a variant form of hairy-cell leukemia, there are high numbers of circulating hairy cells, and the response to pentostatin or cladribine is poor.<sup>12,14</sup>

Classic or variant hairy cells are virtually always strongly positive for CD22, an adhesion molecule expressed exclusively on B cells.<sup>15-19</sup> To target CD22-expressing cells, we designed a recombinant immunotoxin, RFB4(dsFv)-PE38 (BL22), that contains the variable domain (Fv) of the anti-CD22 monoclonal antibody RFB4.<sup>20,21</sup> The Fv is fused to a fragment of *Pseudomonas* exotoxin called PE38, which contains domains responsible for cell death but lacks the domain necessary for cell binding (Fig. 1).<sup>22</sup> BL22 induced complete remissions in mice with a B-cell lymphoma and killed fresh human malignant B cells in vitro.<sup>23,24</sup> To assess the clinical activity of BL22, we studied patients with hairy-cell leukemia that was resistant to cladribine in a dose-escalation trial.


## METHODS

Of the 31 patients with B-cell cancers who were enrolled in a dose-escalation trial of BL22, 16 had hairy-cell leukemia. All patients had circulating malignant cells that expressed CD22, adequate organ function, and an absence of high levels of neutralizing antibodies against BL22; all were resistant to standard chemotherapy; and all provided written, informed consent.

Between 0.2 and 4.0 mg of BL22, which was produced by the Developmental Therapeutics Program of the National Cancer Institute, was diluted in 50 ml of 0.2 percent albumin in 0.9 percent sodium chloride and administered as a 30-minute intravenous infusion every other day for a total of three doses. To diminish inflammatory adverse effects, all patients who received at least 40 µg of BL22 per kilogram of body weight also received 5 mg of infliximab, the monoclonal antibody to tumor necrosis factor α (TNF-α), per kilogram before and one week after the beginning of each cycle and 12.5 to 25.0 mg of rofecoxib, the nonsteroidal selective inhibitor of cyclooxygenase-2, per day. Patients without neutralizing antibodies who did not have progressive disease<sup>24</sup> could be treated again after restaging at intervals of three weeks or more. After a partial response, patients could receive a total of 16 cycles of BL22, and patients who had a complete response could receive 2 additional cycles. Patients could receive higher doses of BL22 during retreatment if these doses were found to be safe in patients who received them during the initial treatment.

The disease was assessed by computed tomography, flow cytometry to detect hairy-cell-leukemia antigens, and polymerase-chain-reaction (PCR) assay of nucleated blood cells to detect immunoglobulin heavy-chain monoclonality and by histologic examination of bone marrow. The criteria for complete remission were an absence of evidence of disease in radiographic studies and an absence of tumor cells in the bone marrow and peripheral blood according to morphologic criteria, as ascertained at least four weeks after the last dose of BL22.<sup>25</sup> The presence or absence of minimal residual disease in the biopsy specimen of bone marrow was determined

From the Laboratory of Molecular Biology (R.J.K., K.B., D.J.F., I.P.), the Medicine Branch (W.H.W., M.R.), and the Laboratory of Clinical Pathology (M.S.-S.), National Cancer Institute, Bethesda, Md. Address reprint requests to Dr. Kreitman at the National Cancer Institute, Laboratory of Molecular Biology, Bldg. 37, Rm. 4B27, 37 Convent Dr., MSC 4255, Bethesda, MD 20892, or at kreitmar@mail.nih.gov.



**Figure 1.** Action of BL22 on Hairy Cells.

BL22 binds to CD22, enters the cell by endocytosis, and is processed and translocated to the cytosol, where it catalyzes ADP ribosylation of elongation factor 2 (ADP-r-EF2) and causes the death of the leukemic cell.<sup>22</sup>

microscopically by immunohistochemical analysis<sup>26</sup> four weeks or more after the last dose of BL22 as well. Radiologic and biopsy evidence of complete remissions and determinations of whether minimal residual disease was present were independently reviewed by personnel who were unaware of the treatment status of the patients.

The maximal tolerated dose was the highest level at which dose-limiting toxic effects (at least grade 3 according to the Common Toxicity Criteria, version 2.0, with exceptions that are not considered to be dose-limiting<sup>27</sup>) occurred in none or one of six patients during the first cycle. Six patients received the maximal tolerated dose (three infusions of 40  $\mu\text{g}$  per kilogram) in the first cycle. A cytotoxicity assay on Raji cells<sup>27</sup> was used to determine plasma levels of BL22 and neutralizing antibodies. The PCR assay used to detect monoclonal B cells (hairy cells) was not sequence-specific and was performed on DNA extracted from mononuclear cells with the use of primers for framework region 3 and the junctional region of the immunoglobulin heavy-chain gene.

## RESULTS

### Patients

The median age of the patients was 54 years, and the median time from diagnosis was 8 years (Table 1). Hairy cells from all patients were strongly positive for CD22, as measured by fluorescence-activated cell-sort-

er (FACS) analysis. Of the 16 patients, 13 had classic hairy-cell leukemia in which the cells expressed CD25, CD11c, and CD103 and had typical morphologic features. Three patients had variant disease<sup>14</sup> in which the leukemic cells lacked CD25 or CD103 (Patients 4, 7, and 11). Before they were enrolled in the study, the patients had received a median of three courses of treatment with a purine analogue (range, one to seven); all had received and were resistant to cladribine, as defined by an inadequate response (Table 1).

### Dose Levels and Immunogenicity of BL22

BL22 contains a bacterial toxin that is expected to be immunogenic in humans. However, neutralizing antibodies against the toxin were generated in only 4 of the 16 patients (Patients 2, 5, 9, and 12); these antibodies were detected after cycles 4, 1, 2, and 4, respectively (Table 2). Patient 5 had a low level of neutralizing antibodies before receiving BL22 and had an anamnestic response during the first cycle. The limited immunogenicity of BL22 made possible the administration of repeated cycles.

### Response to BL22

Of the 16 patients, 11 had a complete remission and 2 had a partial remission. These two patients are still receiving treatment. The remaining three patients received 2 or 6  $\mu\text{g}$  of BL22 per kilogram or had neutralizing antibodies before therapy was started. Residual hairy cells were always strongly positive for CD22. Patients 2 and 5 had 98.0 and 99.5 percent reductions in circulating hairy cells, respectively, but had less than 50 percent decreases in the size of abdominal masses and were not retreated because of the presence of neutralizing antibodies (Table 2). In the 13 patients with a complete or partial response, the abnormal findings on radiography disappeared. Splenomegaly resolved in all eight patients whose spleens had not been surgically removed (Table 1). As Figure 2 shows, the absolute neutrophil count, platelet count, and hemoglobin level improved after treatment. Three patients (Patients 7, 9, and 15) had iron deficiency after treatment with BL22, which may have limited the improvement in hemoglobin levels.

As Table 3 shows, six patients had a complete remission after receiving only one cycle of BL22, whereas in five patients the remission occurred after two to nine cycles. In patients who had a response, the rapid reduction in circulating hairy cells was consistent with a direct cytotoxic effect of BL22. Levels of circulating malignant cells were measured by flow cytometry, which can detect levels of monoclonal B cells of 0.01 to 0.05 percent. In most patients there was more than a 90 percent reduction in such cells by day 3 of cycle 1 (the effect of a single dose) and more than a 99 percent reduction by day 8. Patients 9, 13, and 16 had no detectable monoclonal B cells by day 8. In Patients 4, 7, and 11, all of whom had the variant form of hairy-

**TABLE 1. CLINICAL CHARACTERISTICS OF PATIENTS WITH HAIRY-CELL LEUKEMIA AT THE INITIATION OF TREATMENT WITH BL22.**

PATIENT No.	AGE (YR)/SEX	YEARS AFTER DIAGNOSIS	PRIOR TREATMENT	CIRCULATING HAIRY-CELL COUNT cells/mm <sup>3</sup>	SITES OTHER THAN BLOOD OR MARROW WITH HAIRY CELLS
1*	71/F	37	Splenectomy, interferon alfa, four courses of cladribine, two courses of pentostatin, one course of cladribine, rituximab	88,000	None
2*	54/M	18	Splenectomy, interferon alfa, one course of pentostatin, two courses of cladribine, anti-B4-blocked ricin, four courses of cladribine	690	Abdominal mass
3†	42/F	3	Three courses of cladribine	11	Spleen
4‡§	46/M	9	Interferon alfa, two courses of cladribine, two courses of pentostatin, fludarabine, fludarabine and chlorambucil, chlorambucil, rituximab, one course of pentostatin, interferon alfa	132,000	Spleen
5¶	54/M	25	Splenectomy, one course of cladribine, interferon alfa	180	None
6†	61/M	9	Two courses of cladribine, interferon alfa	1,330	Spleen
7‡	70/M	2	Two courses of cladribine, interferon alfa, one course of cladribine	32,000	Spleen
8‡	50/M	2	One course of cladribine	46	Spleen
9‡	45/F	11	Two courses of cladribine, interferon alfa, one course of pentostatin	22	Spleen
10*	59/M	25	Chlorambucil and prednisone, splenectomy, chlorambucil, interferon alfa, one course of cladribine, one course of pentostatin, one course of cladribine	4,700	None
11‡	56/M	2	One course of cladribine, splenectomy	44,000	Abdominal mass
12‡	43/M	5	Two courses of cladribine, prednisone, interferon alfa	9	Spleen
13‡	57/F	5	One course of cladribine, interferon alfa, splenectomy	38	None
14‡	37/M	0.5	One course of cladribine, rituximab	26	Spleen
15*	54/M	6	Two courses of cladribine	65	Spleen
16*	55/M	21	Splenectomy, three courses of cladribine	6	None

\*The patient had no response to the last course of cladribine.

†The patient had a complete response to the last course of cladribine that lasted less than six months and then relapsed.

‡The patient never had a complete remission.

§The spleen was removed after the third course of BL22 to resolve coagulopathy related to hairy-cell leukemia.

¶Complete remission was never documented.

cell leukemia, the number of circulating hairy cells began to decrease within 24 hours after the first dose. All three patients with the variant form had never had a complete remission with chemotherapy but had a complete remission with BL22.

#### Minimal Residual Disease

The presence of minimal residual disease in the bone marrow, as detected by immunohistochemical analysis, is associated with relatively short durations of complete remission in patients with hairy-cell leukemia.<sup>26</sup> We assessed marrow-biopsy specimens using immunohistochemical analysis with CD20 (L26) and CD3 (Leu4) antibodies; only 1 of 11 patients in complete remission had evidence of minimal residual disease in the bone

marrow (Table 3). Tests for the presence of monoclonal B cells by flow cytometry of blood were negative in 10 of the 11 patients who had complete remissions. A population of hairy cells too low to quantitate (less than 0.05 percent) was detected in one patient. PCR studies, which can detect levels of hairy cells of 0.001 to 0.1 percent, failed to detect monoclonal B cells in the peripheral blood in any of the 11 patients in complete remission.

#### Relapse

Of the 11 patients in complete remission, 3 (Patients 4 and 7, who had variant disease, and Patient 12, who had classic disease) relapsed 8, 12, and 7 months, respectively, after complete remission was achieved. Pa-

**TABLE 2.** DOSE LEVELS, IMMUNOGENICITY, AND DOSE-LIMITING TOXIC EFFECTS OF BL22 IN PATIENTS WITH HAIRY-CELL LEUKEMIA.

PATIENT No.	DOSE* μg/kg	ANTIBODY RESPONSE†	DOSE-LIMITING TOXIC EFFECTS
1	3		
2	6 (4 cycles), 10	Low level of activity after cycle 4	
3	10 (2 cycles), 20 (2 cycles)		
4	30 (9 cycles), 40, 50, 40 (3 cycles)		
5	30 (2 cycles)	High level of activity after cycle 1	Grade 3 hypotension, bone pain, vascular-leak syndrome with grade 1 weight gain
6	30 (3 cycles)		
7	30 (6 cycles), 40 (3 cycles)		
8	30 (2 cycles)		Hemolytic-uremic syndrome‡
9	40 (2 cycles)	High level of activity after cycle 2	
10	40 (2 cycles), 50, 40 (2 cycles)		
11	50 (2 cycles), 40		
12	50 (2 cycles), 40 (3 cycles)	Low and high levels of activity after cycles 4 and 5, respectively	
13	50 (2 cycles)		Hemolytic-uremic syndrome§
14	40 (15 cycles)		
15	40 (13 cycles)		
16	40 (2 cycles)		

\*The amount of BL22 administered intravenously three times per cycle is indicated. Cycle 2 for Patients 5 and 7 was limited to 1 and 2 doses, respectively. Patients 4, 7, and 12 received 3 cycles, 4 cycles, and 3 cycles of BL22, respectively, after relapsing.

†High and low levels of neutralizing-antibody activity indicate over 75 percent and 25 to 75 percent neutralization of 1 μg of BL22 per milliliter of serum, respectively.

‡Toxic effects were characterized by an acute exacerbation of chronic pancreatitis, grade 3 thrombocytopenia, proteinuria, hemolysis, grade 2 hyperbilirubinemia, and grade 1 creatinine elevation.

§Toxic effects were characterized by grade 3 thrombocytopenia, proteinuria, hemolysis, and creatinine elevation and by grade 2 hyperbilirubinemia.

tient 12 had received only one cycle after entering a complete remission and was the only patient with a complete response who was found to have minimal residual disease on bone marrow biopsy. When retreated, Patients 4, 7, and 12 had another complete remission after one to three cycles; Patient 12 had had a response to retreatment.

#### Toxicity of BL22


BL22 caused a dose-limiting cytokine-release syndrome, defined by fever, hypotension, and myalgia or

arthralgia, in Patient 5. This complication was temporally related to a secondary immune response to BL22. The level of TNF-α in this patient (112 pg per milliliter) was elevated (normal level, less than 5 pg per milliliter). To prevent the cytokine-release syndrome, Patients 8 through 16 were pretreated with rofecoxib and infliximab. In Patients 8 and 13, a serious but completely reversible hemolytic-uremic syndrome, confirmed by renal biopsy, developed after the last dose during cycle 2 (Table 2). These two patients required 6 to 10 days of plasmapheresis but not dialysis. Both patients remain in complete remission more than 11 and 16 months after treatment. Hematologic toxic effects (neutropenia, anemia, or thrombocytopenia) and decreases in the T-cell count were not observed in the other 14 patients. Less serious toxic effects included transient hypoalbuminemia, elevations in aminotransferase levels, nausea, myalgia, edema, and slight elevations in creatinine levels; all were reversible.

#### DISCUSSION

We found that a recombinant immunotoxin, BL22, is active in patients with hairy-cell leukemia that is resistant to treatment with purine analogues. BL22 induced a complete remission in 11 of 16 such patients (69 percent) and a partial remission in 2. The three patients who did not have a response probably received inadequate treatment because preexisting toxin-neutralizing antibodies were present or low doses of the immunotoxin were administered. A potential confounding variable was the use of inhibitors of TNF-α in some patients to prevent the cytokine-release syndrome. Although TNF-α is considered an autocrine growth factor for hairy cells and moderate antitumor activity has been reported with inhibition of TNF-α,<sup>28</sup> we believe it is unlikely that the use of infliximab or rofecoxib can account for our results, because four patients had already had a response before infliximab was administered. Of the 11 patients who had a complete response to BL22, 7 had never previously had a complete remission, 2 had had no response to their last course of therapy with a purine analogue, and 2 had had complete remissions lasting less than six months (Table 1). We are unaware of any other treatment, including interferon alfa, fludarabine, chlorambucil, and multiagent chemotherapy, that can produce a high rate of complete remission in patients with hairy-cell leukemia that is resistant to purine analogues. Complete remissions also occurred in all three patients with variant hairy-cell leukemia, which responds poorly to pentostatin<sup>12</sup> and cladribine.<sup>14,29,30</sup>

Up to 50 percent of patients who have a complete response to cladribine or pentostatin still have minimal residual disease detectable by immunohistochemical analysis of bone marrow; this finding portends a decreased rate of disease-free survival.<sup>26,31,32</sup> By contrast, minimal residual disease was present in the bone marrow of only 1 of our 11 patients who had a com-



**Figure 2.** Response of Patients with Pancytopenia to BL22.

Improvement in the absolute neutrophil count (Panel A), the platelet count (Panel B), and the hemoglobin level (Panel C) is shown for Patients 3, 4, 6 through 13, and 16 after treatment with BL22 leading to complete remission and for Patients 14 and 15 after treatment leading to partial remission. Horizontal bars indicate median values. Differences between values measured before and after treatment with BL22 were significant ( $P < 0.01$  for Panels A and B and  $P < 0.004$  for Panel C, by the Mann-Whitney rank-order test).

plete response. Despite the elimination of minimal residual disease by purine analogues, hairy cells can be detected in the marrow by sensitive PCR techniques.<sup>33,34</sup>

The low level of toxicity of BL22 made possible the administration of multiple cycles to most patients. This is potentially a major advantage over cladribine and pentostatin, both of which cause considerable myelosuppression and long-term reductions in CD4+ T cells.<sup>35,36</sup> Although we were limited by our protocol to two cycles of consolidation therapy regardless of the presence or absence of minimal residual disease, additional cycles may be useful, particularly in patients with variant disease, if relapse is frequent after treatment with BL22. Additional follow-up of these patients and treatment of new patients will be necessary to determine whether there is a dose response.

We recently reported that the recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2), which contains an anti-CD25 Fv fused to a truncated pseudomonas

exotoxin (PE38), induced one complete remission and three partial remissions in four patients with hairy-cell leukemia that was resistant to treatment with cladribine.<sup>27,37</sup> Like LMB-2,<sup>19</sup> BL22 is specifically cytotoxic to primary cultures of hairy cells (data not shown), suggesting that clinical responses are due to internalization of BL22 by malignant cells. The response of hairy-cell leukemia to these new agents suggests the potential for targeting other diseases with the truncated toxin PE38. Because CD22 is expressed in all patients with hairy-cell leukemia and at higher concentrations than CD25, BL22 is the preferable recombinant immunotoxin for the treatment of this disease.

The cause of hemolytic-uremic syndrome in two of our patients, both of whom recovered fully and had complete remissions, is unknown. Fatal hemolytic-uremic syndrome was reported with the combination of the immunotoxins RFB4-deglycosylated ricin A chain (directed against CD22) and HD37-deglycosylated ricin A chain (directed against CD19) known

TABLE 3. RESPONSE TO BL22 IN PATIENTS WITH HAIRY-CELL LEUKEMIA.\*

PATIENT No.	STANDARD CRITERIA RESPONSE	MINIMAL RESIDUAL DISEASE		BIOPSY OF BONE MARROW	FACS ANALYSIS OF BLOOD	PCR ANALYSIS OF BLOOD
		CYCLES BEFORE COMPLETE REMISSION	DURATION OF RESPONSE (MO)			
1	Progressive disease	NA	NA	ND	+	ND
2	Marginal response	NA	4	ND	+	ND
3	Complete remission	2	>22	—	—	—
4	Complete remission	9	8, >3	—	—	—
5	Marginal response	NA	4	ND	+	ND
6	Complete remission	1	>20	—	—	—
7	Complete remission	4	12, >4	—	+	—
8	Complete remission	1	>6	—	—	—
9	Complete remission	1	>14	—	—	—
10	Complete remission	3	>12	—	—	—
11	Complete remission	1	>13	—	—	—
12	Complete remission	1	7, >2	+	—	—
13	Complete remission	2	>11	—	—	—
14	Partial remission	NA	>11	+	—	—
15	Partial remission	NA	>11	+	—	—
16	Complete remission	1	>11	—	—	—

\*Marginal response indicates a 98.0 to 99.5 percent reduction in circulating hairy cells. Patients 4, 7, and 12 each had a second complete remission. Determinations of minimal residual disease were either positive (+), negative (—), or not determined (ND). FACS denotes fluorescence-activated cell-sorting, PCR polymerase chain reaction, and NA not applicable.

as Combotox,<sup>38</sup> suggesting a CD22-related mechanism.<sup>39</sup> Since we began taking precautions to prevent renal injury, including improving hydration and avoiding the use of intravenous contrast medium immediately before treatment with BL22, we have seen no other cases of hemolytic-uremic syndrome in 63 cycles of three doses of 40 to 50  $\mu$ g per kilogram. Nevertheless, the hemolytic-uremic syndrome remains a serious potential complication; in our opinion, however, the responses to BL22 justify its testing in patients with a poor prognosis.

Unlike conjugates containing the deglycosylated ricin A chain,<sup>20,21,40,41</sup> the smaller BL22 molecule containing PE38 did not cause pulmonary edema, a serious complication of vascular-leak syndrome; this may have allowed patients with the hemolytic-uremic syndrome to recover. The absence of fatal vascular-leak syndrome with BL22 is consistent with the sensitivity of human umbilical-vein endothelial cells to the deglycosylated ricin A chain and their resistance to PE38.<sup>42,43</sup>

Supported by the National Cancer Institute.

Drs. FitzGerald and Pastan hold the partial patent rights to the invention of the truncated pseudomonas exotoxin.

We are indebted to Dr. Toby Hecht, Dr. Steve Giardina, and Daniel Coffman at the Monoclonal Antibody and Recombinant Protein Facility, Frederick, Md.; to Drs. Carolyn Laurencot, Jay Greenblatt, and Thomas Davis at the Cancer Therapy Evaluation

Program, Bethesda, Md.; to Dr. David Waters at Science Applications International, Frederick, Md.; to Inger Margulies for technical assistance; to Drs. Charles Dinarello and Ellen Vitetta for helpful discussions regarding inflammatory toxic effects; to Dr. Pierre Noel for reviewing bone marrow-biopsy specimens; to Dr. Peter Choyke for reviewing radiologic results; to Lynn Sorbara and Dr. Kakushi Matsushita for performing PCR and cytokine assays; and to associate investigators Diana O'Hagan, Michelle Zancan, and Katura Fetterson for patient care and for assembling clinical data on patients who were retreated.

## REFERENCES

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. *Blood* 1958;13:609-30.
2. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. *Cancer Res* 1990;50:3605-9.
3. Flandrin G, Sigaux F, Sebahoun G, Bouffette P. Hairy cell leukemia: clinical presentation and follow-up of 211 patients. *Semin Oncol* 1984;11: Suppl 2:458-71.
4. Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). *Leuk Lymphoma* 1994;13:307-16.
5. Bouroncle BA. The history of hairy cell leukemia: characteristics of long-term survivors. *Semin Oncol* 1984;11:Suppl 2:479-85.
6. Spiers ASD, Moore D, Cassileth PA, et al. Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). *N Engl J Med* 1987;316: 825-30.
7. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. *N Engl J Med* 1990;322:1117-21.
8. Golomb HM, Jacobs A, Fefer A, et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. *J Clin Oncol* 1986; 4:900-5.
9. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. Alpha interferon for induction of remission in hairy-cell leukemia. *N Engl J Med* 1984;310:15-8.
10. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of

- pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. *J Clin Oncol* 1995;13:974-82.
11. Tallman MS, Peterson LC, Hakimian D, Gillis S, Polliack A. Treatment of hairy-cell leukemia: current views. *Semin Hematol* 1999;36:155-63.
  12. Catovsky D, Marutes E, Talavera JG, et al. Long term results with 2'-deoxycoformycin in hairy cell leukemia. *Leuk Lymphoma* 1994;14:Suppl 1:109-13.
  13. Saven A, Burian C, Koziol JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. *Blood* 1998;92:1918-26.
  14. Blasinska-Morawiec M, Robak T, Krykowski E, Hellmann A, Urban-ska-Rys H. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine — a report of three cases. *Leuk Lymphoma* 1997;25:381-5.
  15. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. *Cancer Res* 1991;51:4052-8.
  16. Clark EA. CD22, a B cell-specific receptor, mediates adhesion and signal transduction. *J Immunol* 1993;150:4715-8.
  17. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. *Blood* 1993;82:1277-87.
  18. Cordone I, Annino L, Masi S, et al. Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia. *J Clin Pathol* 1995;48:955-60.
  19. Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). *Clin Cancer Res* 2000;6:693-700.
  20. Amlot PL, Stone MJ, Cunningham D, et al. A phase I study of an anti-CD22-dglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. *Blood* 1993;82:2624-33.
  21. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. *Blood* 1995;85:3457-65.
  22. Kreitman RJ. Immunotoxins in cancer therapy. *Curr Opin Immunol* 1999;11:570-8.
  23. Kreitman RJ, Wang QC, FitzGerald DJP, Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. *Int J Cancer* 1999;81:148-55.
  24. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJP, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemia. *Clin Cancer Res* 2000;6:1467-87.
  25. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. *J Clin Oncol* 1999;17:1244. [Erratum, *J Clin Oncol* 2000;18:2351.]
  26. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. *Clin Cancer Res* 1999;5:1665-70.
  27. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. *J Clin Oncol* 2000;18:1622-36.
  28. Huang D, Reittie JE, Stephens S, Hoffbrand AV, Brenner MK. Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. *Br J Haematol* 1992;81:231-4.
  29. Rak K, Kiss A, Posa E, Telek B, Szakall S, Ujj G. Hairy cell leukemia variant treated with success by 2-chlorodeoxyadenosine. *Blood* 1998;92:Suppl 1:282b. abstract.
  30. Tetreault S, Saven A. Treatment of hairy cell leukemia-variant (HCL-V) with cladribine. *Blood* 1998;92:Suppl 1:283b. abstract.
  31. Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. *Blood* 1994;84:4310-5.
  32. Wheaton S, Tallman MS, Hakimian D, Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. *Blood* 1996;87:1556-60.
  33. Filleul B, Delannoy A, Ferrant A, et al. A single course of 2-chlorodeoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. *Leukemia* 1994;8:1153-6.
  34. Carbone A, Reato G, Di Celle PF, Lauria F, Foa R. Disease eradication in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. *Leukemia* 1994;8:2019-20.
  35. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. *Blood* 1994;83:2906-11.
  36. Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. *Leukemia* 1997;11:42-7.
  37. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. *Blood* 1999;94:3340-8.
  38. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-dglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. *Clin Cancer Res* 2000;6:1302-13.
  39. Schwager I, Jungi TW. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. *Blood* 1994;83:152-60.
  40. Conry RM, Khazaali MB, Saleh MN, et al. Phase I trial of an anti-CD19 dglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. *J Immunother Emphasis Tumor Immunol* 1995;18:231-41.
  41. Stone MJ, Sausville EA, Fay JW, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. *Blood* 1996;88:1188-97.
  42. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. *Proc Natl Acad Sci U S A* 1999;96:3957-62.
  43. Kuan C-T, Pai LH, Pastan I. Immunotoxins containing *Pseudomonas* exotoxin that target Le<sup>x</sup> damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. *Clin Cancer Res* 1995;1:1589-94.

Copyright © 2001 Massachusetts Medical Society.